Form 4: Gyre Therapeutics President Sells Shares Under 10b5-1 Plan

Songjiang Ma, President of Gyre Therapeutics, sold shares of common stock between December 17 and December 18, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Songjiang Ma, President of Gyre Therapeutics, sold shares of the company's common stock on December 17 and 18, 2024.
• The sales were executed under a Rule 10b5-1 trading plan adopted on September 13, 2024.
• On December 17, 2024, 1,212 shares were sold at a weighted average price of $10.94, with individual prices ranging from $10.10 to $11.095.
• An additional 788 shares were sold on December 17, 2024, at a weighted average price of $11.23, with individual prices ranging from $11.10 to $11.37.
• On December 18, 2024, 1,571 shares were sold at a weighted average price of $11.17, with individual prices ranging from $10.70 to $11.69.
• Finally, 429 shares were sold on December 18, 2024, at a weighted average price of $12.11, with individual prices ranging from $11.70 to $12.46.
• Following these transactions, Mr. Ma indirectly owns 2,938,467 shares through his spouse.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to insider trading. The sentiment is neutral as it simply reports transactions.

Industry Context

Insider selling can sometimes be viewed negatively by the market, but the existence of a 10b5-1 plan suggests the sales were pre-planned and not based on current inside information. It is common for executives to use 10b5-1 plans to diversify their holdings or for personal financial planning.

Stakeholder Impact

• Shareholders may react to the news of insider selling, although the existence of a 10b5-1 plan may mitigate concerns.
• The impact on employees, customers, suppliers, and creditors is likely to be minimal.

Key Dates